Enhanced Risk of Gastroesophageal Reflux Disease and Esophageal Complications in the Ulcerative Colitis Population

Xiaoliang Wang1,2, Omar Almetwali2, Jiayan Wang2

  • 1Gastroenterology, Hepatology & Nutrition, Digestive Disease & Surgery Institute, Cleveland Clinic Main Campus, Cleveland, OH 44195, USA.

PubMed

Insights

Patients with ulcerative colitis (UC) have a higher risk of developing gastroesophageal reflux disease (GERD) and its complications, including esophageal stricture and Barrett's esophagus. Early monitoring and intervention are crucial for managing these GERD-related risks in UC patients.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Epidemiology

Background:

  • Heartburn and reflux are common in ulcerative colitis (UC) patients, but the link to gastroesophageal reflux disease (GERD) and its complications remains unclear.
  • Understanding the correlation between UC and GERD, esophageal stricture, and Barrett's esophagus (BE) is essential for patient management.

Purpose of the Study:

  • To investigate the prevalence of GERD and its complications in patients diagnosed with ulcerative colitis.
  • To determine the associated risks of developing GERD and esophageal complications within the UC population.

Main Methods:

  • Analysis of the National Inpatient Sample (NIS) dataset, including over 7 million patients.
  • Comparison of GERD prevalence and occurrence of esophageal complications between UC patients and non-UC patients.
  • Bivariate analyses using chi-squared or Fisher exact tests to assess statistical significance.

Main Results:

  • UC patients exhibited a significantly higher prevalence of GERD (23.0% vs. 16.5%), non-erosive reflux disease (NERD) (22.3% vs. 16%), and erosive esophagitis (EE) (1.2% vs. 0.6%).
  • UC patients showed increased odds of developing GERD (OR 1.421), NERD (OR 1.407), and EE (OR 1.681).
  • A higher prevalence of esophageal stricture and Barrett's esophagus without dysplasia was observed in UC patients, with significantly increased odds for BE (OR 1.892).

Conclusions:

  • This study confirms an elevated risk of GERD and its associated esophageal complications in individuals with ulcerative colitis.
  • Findings underscore the necessity for proactive surveillance and timely interventions to mitigate GERD-related risks in the UC patient cohort.

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
148
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
375